The global e-prescribing market testing was valued at ~US$ 1.5 billion in 2021. The market is expected to witness a CAGR of 23.9% from 2022 to 2030. 

Among medication errors, prescription faults are the foremost causes of concern for healthcare professionals worldwide, as they account for over 70% of medication errors reported by hospitals & general practice settings. Although these errors are rarely fatal, they can have serious adverse effects on a patient’s health. In addition to the associated risk for a patient’s health, prescription errors are also a common cause of medical & legal malpractice claims against healthcare professionals & doctors.

Growing opioid crisis in the U.S. is a major concern driving growth of e-prescribing technology. Electronic Prescription in Controlled Substances (EPCS) provides a transparent, secure system that makes it comparatively easier to prescribe various controlled substances to the patients who legitimately need them, at the same time making it more difficult to commit abuse or fraud. For instance, according to Surescipt estimates in 2018, the opioid epidemic touched crisis proportions and costs the U.S. more than USD 500 billion every year.

Get Sample PDF of the Report: - https://growthplusreports.com/inquiry/request-sample/e-prescribing-market/7883

Key Players

  • Cerner Corporation
  • Practice Fusion Inc.
  • Allscripts Healthcare Solutions Inc.
  • Epic Systems Corporation
  • Athenahealth Inc.
  • eClinicalWorks
  • Medical Information Technology Inc.
  • GE Healthcare
  • McKesson Corporation
  • DrFirst Inc.
  • Henry Schein Inc.
  • Networking Technology Inc. (RXNT)
  • Surescripts-RxHub LLC
  • NextGen Healthcare

 

E-prescribing Market by Component

 

  • Software
  • Services

By Mode of Delivery

  • On-Cloud Based Delivery
  • On-Premises Based Delivery

Key Reasons to Purchase:

  • To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.
  • Assess the production processes, major issues, and solutions to mitigate the development risk.
  • To understand the most affecting driving and restraining forces in the E-prescribing Market and its impact in the global market.
  • Learn about the market strategies that are being adopted by leading respective organizations.
  • To understand the outlook and prospects for the market.

Key Questions Answered in the Report Include:

  • This report gives all the information about the industry analysis, revenue, and overview, of this market.
  • What will be the rate of increase in market size and growth rate by the end of the forecast period?
  • What is the major global E-prescribing Market trends influencing the development of the market?
  • What are the vital results of SWOT analysis of the major players operating in the E-prescribing Market?
  • What are the potential growth opportunities and threats faced by Major competitors in the market?

TOC of E-prescribing Market

1 Scope of the Report

1.1 Market Ecosystem

1.2 Geographic Scope

1.3 Timeline Under Consideration

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 E-prescribing Market Executive Summary

2.1 World Market Overview

2.1.1 Global Market Size 2022-2030

2.1.2 Market Size CAGR by Region 2020 VS 2028

2.2 E-prescribing Market Segment by Type

2.2.1 Type 1

2.2.2 Type 2

 

Browse the full Report now: - https://growthplusreports.com/report/e-prescribing-market/7883

 

About Us

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.